Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

ABSTRACT: Recent developments have set the stage for immunotherapy as a supplement to conventional cancer treatment. Consequently, a significant effort is required to further improve efficacy and specificity, particularly the identification of optimal therapeutic targets for clinical testing. Cancer/testis antigens are immunogenic, highly cancer-specific, and frequently expressed in various types of cancer, which make them promising candidate targets for cancer immunotherapy, including cancer vaccination and adoptive T-cell transfer with chimeric T-cell receptors. Our current understanding of tumor immunology and immune escape suggests that targeting oncogenic antigens may be beneficial, meaning that identification of cancer/testis antigens with oncogenic properties is of high priority. Recent work

SUBMITTER: Gjerstorff MF 

PROVIDER: S-EPMC4599236 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature